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Abstract  
Background: HIV-associated lipodystrophy is associated with decreased expression of 1 
PPAR-γ in adipose tissue. Conjugated linoleic acid (CLA) isomers (cis9, trans11 and 2 
trans10, cis12) are putative PPAR-γ agonists, but have not previously been investigated in 3 
the context of HIV-associated lipodystrophy.  4 
Methods: 3T3-L1 pre-adipocytes were differentiated in the presence of ritonavir (20 μM as 5 
per previous experimental models) and 100 μM cis9,trans11, trans10,cis12 or vehicle 6 
control, DMSO. Microarray analysis, RT-PCR, DNA binding ELISA and Oil Red O staining 7 
were used to investigate adipocyte gene expression and binding, protein secretion and 8 
triglyceride storage. 9 
Results: trans10,cis12 + ritonavir altered the expression of 2160 gene transcripts greater than 10 
1.5-fold compared with control, while 257 gene transcripts were altered by cis9,trans11 + 11 
ritonavir (P<0.001). trans10,cis12 + ritonavir down-regulated Pparg (–1.55) and Adipoq (-12 
2.95), as well as differentiation (Fcor (-4.78-fold), Arl4a (-4.84), Itga6 (-2.45), Id4 (-2.01)) 13 
and triglyceride storage genes (Mrap (-8.25), Scd1 (-4.34), Lipin1 (-2.52)). Changes in 14 
Adipoq were confirmed by RT-PCR (P=0.038) and adiponectin secretion by ELISA 15 
(P=0.003). cis9,trans11 + ritonavir increased PPAR-γ nuclear binding to its gene response 16 
element (P=0.038). Both isomers increased triglyceride storage in the presence of ritonavir 17 
(P<0.001 and P=0.001, respectively).  18 
Conclusion: In the presence of ritonavir, trans10, cis12 appears to be detrimental, while cis9, 19 
trans11 was beneficial and may mediate its effects via PPAR-γ. Further research is required 20 
to determine the potential role of CLA isomers as therapeutic agents in the management of 21 
HIV-associated lipodystrophy.   22 
  23 
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 Introduction 24 
Conjugated linoleic acid (CLA) consists of positional and stereo-isomers of linoleic acid 25 
formed by bacterial biohydrogenation of linoleic acid in the rumen [1]. The cis9, trans11 26 
(c9,t11) and trans10, cis12 (t10,c12) isomers are the most biologically active [1]. CLA 27 
isomers have been shown to decrease adipocyte size and lipid accumulation [2], as well as 28 
metabolic parameters including triglyceride (TG), non-esterified fatty acid, glucose and 29 
insulin concentrations [3]. The anti-obesity effect of CLA isomers has been extensively 30 
investigated, yet results are inconclusive. This may relate to the fact that c9,t11 and t10,c12 31 
are often provided in combination, yet they exert differential effects on adipocyte gene 32 
expression [4-6]. t10,c12 appears to be the most potent isomer and decreases lipid 33 
accumulation, while c9,t11 has been shown to promote lipid accumulation [7]. The 34 
differential effects of the isomers may be mediated by PPAR-γ, as t10,c12 has been shown to 35 
down-regulate expression of the transcription factor [4], while c9,t11 is a putative agonist [8-36 
12].  37 
 38 
HIV-associated lipodystrophy syndrome (HALS) is the most prevalent sub-type of acquired 39 
lipodystrophy and is associated with HIV infection and the use of highly active antiretroviral 40 
therapy (HAART) [13]. HAART consists of a combination of antiretroviral drugs (ARVs), 41 
typically chosen from one of three main drug classes: nucleoside reverse transcriptase 42 
inhibitors (NRTI), protease inhibitors (PI) and non-nucleoside reverse transcriptase inhibitors 43 
(NNRTI) [14]. Ritonavir (RTV) is a PI routinely used as a boosting agent to increase the 44 
plasma concentrations of other PI, thereby reducing their dose and frequency of use, and 45 
increasing clinical efficacy [15].  46 
 47 
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HALS manifests in different subtypes, which include lipoatrophy of the face and limbs, and 48 
lipohypertrophy of the abdomen. Additionally, morphological abnormalities also occur such 49 
as dyslipidaemia, insulin resistance and impaired glucose tolerance, hypertension, endothelial 50 
dysfunction, and altered cytokine and adipokine production [16]. The adverse effects 51 
associated with HAART affect up to 83% of treated individuals [17] and increase the risk of 52 
premature cardiovascular disease [18]. Use of RTV is associated with greater adverse effects 53 
[19]. In-vitro RTV decreases PPAR-γ gene expression in subcutaneous adipocyte cultures 54 
[20] and alters the expression and secretion of adiponectin, glucose metabolism genes and 55 
pro-inflammatory cytokines [21]. We have previously investigated the effect of physiological 56 
concentrations of RTV in 3T3-L1 adipocytes and identified significant down-regulation of 57 
gene transcripts involved in adipocyte differentiation, including PPAR-γ and adiponectin, 58 
compared with control [22].  59 
 60 
The potential role of CLA isomers in mitigating the detrimental effects of RTV has not 61 
previously been investigated in vitro, nor has it been investigated in vivo in patients with 62 
HIV-associated lipodystrophy. This novel study aimed to determine the effect of CLA 63 
isomers on adipocyte function and gene expression in an in-vitro model of HIV-associated 64 
lipodystrophy with the overall goal of establishing mechanisms, which may be further 65 
investigated with a view to therapeutic implementation of CLA supplementation in vivo.  66 
67 
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2. Materials and Methods 68 
 69 
2.1. Cell culture and treatment 70 
Murine 3T3-L1 adipocytes were chosen for the current experiments as they show homology 71 
to human adipocytes. 3T3-L1 cells exhibit properties typical of adipocytes in vivo, such as 72 
insulin-stimulated glucose uptake, lipogenesis, catecholamine-stimulated lipolysis and 73 
adipokine secretion. Microarray analysis has previously been carried out in 3T3-L1 cells in 74 
the context of inflammation [23] and triglyceride synthesis [24]. Additionally, our group [22] 75 
and others [21, 25, 26, 27] have previously investigated the effect of ARVs in 3T3-L1s 76 
including microarray analysis. The effect of CLA has also been investigated using this 77 
murine model [4, 28, 29]. Therefore, the 3T3-L1 cells were considered an appropriate model 78 
for investigating the effect of both ARV and CLA on adipogenic processes.  3T3-L1 79 
preadipocytes were grown to confluence and induced to differentiate as previously described 80 
[22]. After d 2 of differentiation, the medium was removed and replaced with growth 81 
medium supplemented with insulin (1 μg/ml) and Cmax concentrations of RTV (20 μM; VWR 82 
International, Lutterworth, UK), vehicle control (0.1% ethanol) with or without 100 μM CLA 83 
isomers (c9,t11 or t10,c12; VWR International) or fatty acid vehicle control, DMSO. 84 
Medium was changed every second day thereafter until the adipocytes were fully 85 
differentiated at d 5, as determined by light microscopy. Cells were exposed to the RTV and 86 
CLA for a total of five days. Cell viability was assessed using the MTS Cell Titer 96 87 
Aqueous One Solution assay on d 5 of adipocyte differentiation as previously described [22]. 88 
Cell viability was confirmed for all treatment groups prior to experimental work. 89 
Quadruplicate cell cultures were used for each experimental condition.  90 
 91 
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2.3 RNA extraction and preparation 92 
Total RNA (1 µg) was extracted from adipocytes after 5 days of exposure to antiretroviral 93 
drug, CLA isomer or control using the RNeasy Mini Kit according to manufacturer’s 94 
instructions (Qiagen, Manchester, UK). Briefly, cells were lysed and homogenised using a 95 
highly denaturing guanidine-thiocyanate-containing buffer. Ethanol was added to provide 96 
appropriate binding conditions and the sample was then applied to an RNeasy Mini spin 97 
column. Total RNA binds to the membrane and contaminants were efficiently washed away. 98 
RNA was eluted in 50 μl nuclease-free water. RNA was quantified using the NanoDrop® 99 
1000 3.7.1 (Thermo Scientific, Wilmington, USA). RNA integrity numbers can be found in 100 
Supplementary Table 1. 101 
2.4 Microarray hybridisation and data analysis  102 
Microarray hybridisation was carried out as previously described using Affymetrix 103 
GeneChip® Mouse Genome 430 2.0 Array [22]. The array contained 45,102 probe sets 104 
representing 41, 975 genes, of which 34,000 are well-substantiated mouse genes.  105 
RNA samples were pooled to minimise individual variation as a source of gene-expression 106 
variance (one pool representing four control-treated cells, one representing the four 107 
c9,t11+RTV-treated cells and one representing the four t10,c12+RTV-treated cells). 500 ng 108 
of each of the three pooled samples in 5 μl nuclease-free water was used in the reactions.  109 
Data were analysed using the Robust Multi-array Average approach using quantile 110 
normalisation and the mean change in expression was determined for each gene using the 111 
formula =IF(‘ratio value’<1, -1/’ratio value’, ‘ratio value’) where the ratio value is ratio of 112 
treatment/control. Differentially expressed genes were defined using a threshold of 1.5-fold 113 
relative to control (signal log ratio ≥ 1.0 or ≤ -1.0). MetaCore™ pathway analysis software 114 
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(GeneGo, Thomson Reuters, New York) was used to identify differentially expressed genes 115 
and to classify these genes into clusters based on functionality.  116 
A list of relevant gene ontology (GO) terms describing genes affected by RTV in terms of 117 
their biological function was generated using MetaCore™ software. Affymetrix probe 118 
identifications showing a difference of greater than 1.5-fold between RTV+c9,t11- or 119 
RTV+t10,c12-treated cells and controls were added and  a P value was generated based on 120 
the number of interactions each gene had within the pathway. A false discovery rate (FDR) of 121 
1 was selected to identify all objects with at least one connection with the dataset. Microarray 122 
data are archived with the NCBI Gene Expression Omnibus repository (series record 123 
GSE70854). 124 
 125 
2.5 Real-time RT-PCR 126 
cDNA was generated by reverse transcription using the High Capacity RNA-to-cDNA kit 127 
(Invitrogen Life Technologies) as per manufacturer’s instructions. Real-time RT-PCR was 128 
used to measure PPAR-γ (Mm01184322_m1), adiponectin (Mm00456425_m1) and 129 
endogenous housekeeping control hypoxanthine-guanine phosphoribosyltransferase (Hprt; 130 
Mm 1545399_m1) gene expression using TaqMan® Gene Expression Assays (Invitrogen 131 
Life Technologies). Data were analysed using the 2-ΔΔCT method for target gene expression 132 
normalised to control [30].   133 
 134 
2.6  ELISA  135 
Adiponectin concentration in cell culture media was determined on d 5 of differentiation. 136 
Cell supernatants were extracted, centrifuged at 12,000 rpm for 10 min, aliquoted and stored 137 
at -20°C. Adiponectin concentration in supernatants was determined using the DuoSet® 138 
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ELISA Development kit as per manufacturer’s protocol (R&D Systems Inc., Abingdon, UK). 139 
All samples were analysed in duplicate.  140 
 141 
2.7 Nuclear PPAR-γ activation 142 
Nuclear proteins were extracted from adipocytes on d 5 of differentiation using a nuclear 143 
extract kit as per manufacturer’s protocol (Active Motif, Rixensart, Belgium). The Bradford 144 
assay was used to determine protein concentration as per manufacturer’s instructions (Sigma 145 
Aldrich). 10 μg of nuclear extract from differentiated adipocytes on d 5 of differentiation was 146 
used in a TransAM™ PPAR-γ transcription factor assay (Active Motif, Rixensart, Belgium) 147 
to investigate PPAR-γ nuclear binding to the peroxisome proliferator response element 148 
(PPRE) as per manufacturer’s instructions. Absorbance was measured on the Synergy HT-1 149 
spectrophotometer (Biotek, UK) at 450 nm with a reference wavelength of 655 nm.   150 
2.8 Oil Red O staining 151 
TG accumulation at d 5 of differentiation was determined using ORO staining (Sigma 152 
Aldrich). Briefly, cells were fixed with 10% formalin for 1 h, rinsed with 60% isopropanol 153 
and stained with 60% ORO working solution prepared in isopropanol for 10 minutes. After 154 
washing with distilled water, the ORO was eluted using 100% isopropanol and the optical 155 
density of the solution measured at 540 nm using the Synergy HT-1 spectrophotometer 156 
(Biotek).  Adipocyte images were captured by using a DXM 1200 Digital Camera (Nikon, 157 
Kingston Upon Thames, UK) and a Lucia G Image-Processing System (version 4.61; Nikon). 158 
 159 
2.9 Statistical analysis  160 
Statistical analyses were performed using SPSS software (version 20; IBM, Hampshire, UK). 161 
Data for RT-PCR, ELISA and DNA binding ELISA were analysed using independent 162 
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samples t-tests to compare treatment (RTV + t10,c12 or RTV + c9,t11) with control (RTV + 163 
DMSO). Differences were considered significant if P < 0.05. Data are expressed as the mean 164 
± standard error of the mean (SEM). 165 
 166 
3. Results 167 
3.1. Microarray analysis: c9,t11 and t10,c12 168 
All probe sets which produced an “absent” or “no change” signal compared with control were 169 
removed. Of the remaining probes, those with greater than a 1.5-fold change compared with 170 
control were selected in order to minimise background noise and isolate only significantly 171 
altered gene transcripts.  172 
For t10,c12-treated cells, these probes represented 2160 gene transcripts with altered 173 
expression, of which 1209 (56 %) were down-regulated and 951 (44 %) were up-regulated 174 
compared to control. A full list of probe IDs for the 2160 gene transcripts altered by 175 
RTV+t10,c12 is available online (Supplementary Table 2). The results, showing the 1621 176 
unique gene transcripts and fold changes in expression in t10,c12+ritonavir -treated 177 
compared with control cells, are also available online (Supplementary Table 3).  178 
The addition of c9,t11 to ritonavir-treated cells resulted in 257 gene transcripts with altered 179 
expression compared with control, of which 146 (57 %) were down-regulated and 111 (43 %) 180 
were up-regulated compared to control. A full list of probe IDs for the 257 genes altered by 181 
RTV+c9,t11 is available online (Supplementary Table 4). The results, showing the 207 182 
unique genes and fold changes in expression in c9,t11-treated compared with control cells, 183 
are also available online (Supplementary Table 5).  184 
 185 
3.1.1. Gene ontology 186 
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The main GO processes affected by RTV+t10,c12 or RTV+c9,t11 are listed in Figure 1 and 187 
Figure 2 (all P < 0.001 compared to control). Fat cell differentiation was the top GO process 188 
affected by RTV + t10,c12, while homophilic cell adhesion via plasma membrane adhesion 189 
molecules was the top GO process affected by RTV + c9,t11. Network objects (genes) within 190 
these two main GO processes are listed in Table 1 with their corresponding fold changes.  191 
 192 
3.1.2. Effect of CLA isomers on Pparg and Adipoq expression 193 
The addition of t10,c12 to RTV-treated cells down-regulated Pparg mRNA (-1.55-fold) and 194 
Adipoq (-2.95-fold) mRNA transcripts in microarray analysis compared with control. In 195 
contrast, RTV + c9,t11 up-regulated Pparg, but only by 1.15-fold, which was not detected 196 
using the assigned 1.5-fold change cut-off. No significant effect was observed for c9,t11 + 197 
RTV on Adipoq mRNA transcripts. 198 
RTV + t10,c12 down-regulated a number of gene transcripts involved in adipocyte 199 
differentiation, the main GO process affected. These include melanocortin 2 receptor 200 
accessory protein (Mrap; -8.25-fold), free fatty acid receptor 2 (Ffar2; -4.58-fold), ADP-201 
ribosylation factor-like 4A (Arl4a -4.84-fold), stearoyl-Coenzyme A desaturase 1 (Scd1; -202 
4.34), integrin alpha 6 (Itga6; -2.45-fold) and inhibitor of DNA binding 4 (Id4; -2.01). Pparg 203 
regulatory genes beta-3 adrenergic receptor (Adrb3; -6.36-fold) and lipin 1 (Lpin1; -2.52) 204 
were also down-regulated by RTV + t10,c12. Transcripts for genes involved in insulin 205 
sensitivity (foxo1 corepressor (FCoR; -4.78-fold; Steap4; -4.08-fold) and glucose metabolism 206 
(Glut4; -3.67-fold) were down-regulated by RTV + t10,c12. PPAR-γ target gene and inducer 207 
of adiponectin secretion endoplasmic reticulum oxidoreductase 1-L alpha (Ero1l) was down-208 
regulated by RTV + t10,c12 (-2.49-fold). Lipolysis regulatory genes inhibin beta b (Inhbb) 209 
and Bernardinelli-Seip congenital lipodystrophy 2 homolog were also down-regulated by 210 
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RTV + t10,c12 (-2.89-fold and  -2.29-fold, respectively), as well as the energy metabolism 211 
gene SH2B adaptor protein 2 (Sh2b2 -2.56-fold).  212 
A number of gene transcripts were up-regulated by RTV + t10,c12 including high mobility 213 
group AT-hook 2 (Hmga2; + 6.96-fold), cyclin D1 (Ccnd1; +3.04-fold), inhibin beta-A 214 
(Inhba; +2.09-fold) and guanine nucleotide binding protein, alpha stimulating) complex locus 215 
(Gnas; +1.62-fold).   216 
Within the main GO process affected by c9,t11 + RTV, gene transcripts from the 217 
protocadherin gamma subfamily (Pcdhga) were up-regulated (+1.5-fold). No gene transcripts 218 
were down-regulated greater than 1.5-fold.  219 
 220 
3.2 Validation of microarray by RT-PCR 221 
RT-PCR was used to confirm microarray findings for two genes of interest PPAR-γ and 222 
adiponectin. In the presence of RTV, neither t10,c12 nor c9,t11 exerted a significant effect on 223 
PPAR-γ gene expression in RTV-treated cells (Figure 3). Adiponectin gene expression was 224 
significantly decreased by RTV + t10,c12 compared with control (P = 0.038; Figure 4). 225 
c9,t11 had no significant effect on adiponectin gene expression in the presence of RTV.  226 
 227 
3.3 PPAR- nuclear binding 228 
The effect of CLA isomers on nuclear PPAR-γ binding to the immobilised consensus site 229 
(PPRE) was investigated in adipocytes treated with RTV. c9,t11 significantly increased 230 
nuclear PPAR-γ binding to the immobilised consensus site in both RTV- treated cells (P = 231 
0.038; Figure 5). No significant effect was observed for t10,c12.  232 
 233 
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3.4 Adiponectin secretion 234 
The effect of the CLA isomers on adiponectin secretion was investigated in adipocytes 235 
treated with RTV. t10,c12 significantly decreased adiponectin secretion in RTV-treated cells 236 
(P = 0.003; Figure 6). c9,t11 increased adiponectin by 40%, but this did not reach 237 
significance.  238 
  239 
3.5 Triglyceride accumulation 240 
TG accumulation was investigated in 3T3-L1 adipocytes treated with RTV and CLA isomers 241 
using Oil Red O staining. Under RTV exposure, both c9,t11 and t10,c12 significantly 242 
increased in TG accumulation compared to control cells (P<0.001; Figure 7A and 7B).  243 
244 
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4. Discussion  245 
We have previously shown that RTV alters adipocyte gene expression with detrimental 246 
consequences for the adipocyte [22]. It was hypothesized that the addition of CLA isomers to 247 
RTV-treated adipocytes would modulate some of these detrimental effects. For the first time 248 
in an in-vitro model of HIV-associated lipodystrophy, c9,t11 was found to have a neutral or 249 
beneficial effect, while t10,c12 exerted a detrimental effect on adipocyte differentiation and 250 
gene expression.  251 
Binding of lipophilic ligands to PPAR-γ leads to the transcription of adipogenic genes [31], 252 
which regulates adipogenesis and lipid metabolism [32]. Caron et al [33] highlight a central 253 
role for PPAR-γ down-regulation in the etiology of HALS. In the current study, RTV + 254 
t10c12 down-regulated PPAR-γ mRNA transcripts, as revealed by microarray analysis. In 255 
contrast, RTV + c9,t11 increased PPAR-γ mRNA expression, although this did not reach 256 
significance. A DNA binding assay was used to determine the level of binding of PPAR-γ 257 
mRNA to the PPRE. Interestingly, the addition of c9,t11 to RTV-treated cells significantly 258 
up-regulated PPAR-γ binding to PPRE, despite showing a non-significant effect at the 259 
mRNA level. Previous studies have shown increased PPAR-γ gene expression in c9,t11–260 
treated cells, although in the absence of RTV [9, 10]. Despite an effect at the mRNA level, 261 
t10,c12 did not significantly alter PPAR-γ binding. Previous studies in the literature have 262 
shown decreased PPAR-γ expression [4], mass [34], activation and protein levels [35] in 263 
response to t10,c12, but again in non-RTV-treated cells. 264 
PPAR-γ target gene adiponectin plays a role in insulin sensitization and its down-regulation 265 
may contribute to insulin resistance in HALS [36]. In the current study, adiponectin gene 266 
transcripts were down-regulated in adipocytes treated with RTV + t10,c12 compared with 267 
control in microarray analysis, which may be a consequence of down-regulation of PPAR-γ. 268 
Adiponectin protein secretion was also significantly down-regulated by RTV+t10,c12 269 
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compared with control. Additionally, down-regulation of Ero1l may have contributed to the 270 
reduction in adiponectin mRNA by RTV + t10,c12, as Ero1L has been shown to increase 271 
adiponectin mRNA expression following activation by PPAR-γ in mature adipocytes [37]. 272 
Both antiretroviral drugs [22, 38] and t10,c12 [34] alone have been shown to significantly 273 
decrease adiponectin mRNA expression, therefore, the combination of RTV + t10,c12 would 274 
be expected to result in down-regulation. In the case of RTV+c9,t11, non-significant 275 
increases in adiponectin mRNA expression (29%) and protein secretion (40%) were 276 
observed. These findings correspond with previous research using c9,t11 only in 3T3-L1 277 
adipocytes [5] and in mice [39], and indicates the potential for c9,t11 to overcome the 278 
detrimental effects of RTV on adiponectin.   279 
In the current study, leptin expression was not altered by RTV + CLA. Leptin is another 280 
important adipokine, typically decreased in HALS and leptin administration in HALS was 281 
found to be beneficial in improving lipoatrophy and dyslipidaemia [40, 41]. Previous studies 282 
in 3T3-L1 cells show no effect of ARVs only [22, 42] or c9,t11 only [43] on leptin 283 
expression, but t10,c12 decreased leptin expression in rats [44]. Although c9,t11 may not 284 
increase leptin expression, it appears to be involved in the other mechanisms underlying 285 
adipocyte dysfunction in HALS, including down-regulation of  PPAR-γ.  286 
Similar to adiponectin, melanocortin 2 receptor accessory protein (Mrap) is transcriptionally 287 
activated by PPAR-γ via a PPRE in the Mrap promoter region [45]. Mrap was the top gene 288 
within the main GO process (fat cell differentiation) down-regulated by RTV + t10,c12 (-289 
8.25-fold) in the current study.  Mrap is a G-protein coupled receptor for adrenocorticotropic 290 
hormone [45] and Mrap knockdown in adipocytes is associated with increased lipid droplet 291 
formation, but no change in PPAR- γ expression [46]. In the current study, we observed a 292 
decrease in Mrap mRNA transcripts and PPAR-γ mRNA transcripts, and an increase in TG 293 
accumulation, which corresponds with findings from the study of Betz et al and provide a 294 
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possible explanation for the increase in TG accumulation observed in RTV+t10,c12-treated 295 
cells. Neither t10,c12 nor RTV have previously been investigated in terms of their effect on 296 
Mrap expression.   297 
Following differentiation, lipid metabolism genes orchestrate changes in the adipocyte, which 298 
result in the accumulation of triglyceride within lipid droplets. Lipin-1 (Lpn1) is a 299 
transcriptional coactivator of such lipid metabolism genes and was down-regulated by 300 
RTV+t10,c12 in the current study. In our previous study, RTV down-regulated Lpn1 301 
expression [22] and in the current study t10,c12 was unable to counteract this effect. Down-302 
regulation of Lpn1 may play an important role in the development of adipose tissue 303 
abnormalities in HIV as highlighted by data showing significantly lower Lpn1 mRNA 304 
expression in subcutaneous adipose tissue from patients with HALS compared with those 305 
without HALS [47, 48]. The lipoatrophic effect of RTV+t10,c12 is further demonstrated by 306 
its inhibitory effect on stearoyl-Coenzyme A desaturase 1 (Scd1), as well as anti-lipolytic 307 
genes inhibin  beta b (Ihbb) and Bernardinelli-Seip congenital lipodystrophy 2 homolog 308 
(Bscl2). 309 
In the present study, RTV+c9,t11 did not exert a detrimental effect on adipocytes when 310 
compared with RTV+t10,c12. The main GO process altered by c9,t11 was homophilic cell 311 
adhesion by plasma membrane adhesion molecules and genes from the protocadherin gamma 312 
subfamily were the only genes altered and were up-regulated within this GO process. 313 
Protocadherin gamma is one of a family of cell adhesion proteins and forms part of a 314 
homophilic subset of Pcdhg isoforms with specific roles in intercellular interactions [49]. To 315 
the best of the authors’ knowledge, Pcdhg has not previously been shown to be altered by 316 
either RTV or CLA isomers.  317 
Triglyceride accumulation was investigated to determine whether changes in mRNA 318 
expression of lipid metabolism genes translated to changes in the adipocyte phenotype. RTV 319 
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has been shown to decrease adipocyte TG accumulation [22, 50], and in the current study the 320 
addition of c9,t11 and t10,c12 to RTV-treated cells significantly increased TG accumulation 321 
compared with control. c9,t11 has not previously been shown to affect TG accumulation, 322 
while evidence from the literature strongly supports the anti-lipogenic effect of t10,c12 [4, 7, 323 
26, 51-53]. However, it is important to bear in mind that these studies investigated CLA 324 
isomers alone, without antiretroviral drugs. Down-regulation of Mrap gene transcripts as 325 
discussed above, may have contributed to the increase in TG accumulation. Additionally, it 326 
could be suggested that the effects of t10,c12 may differ depending on prevalent conditions 327 
such as the presence of RTV. This has been observed in a study of porcine peripheral blood 328 
mononuclear cells where the addition of an endotoxin to cells treated with t10,c12 reversed 329 
the effects of the isomer on NF-κB activity and TNF-α expression [54]. Therefore, it is 330 
possible that the presence of RTV in the current study reversed the normal adipocyte 331 
response to t10,c12.  332 
At present, the majority of CLA supplements commercially available consist of either a 333 
mixture of CLA isomers or of the t10,c12 isomer alone, while c9,t11 is the main isomer 334 
found naturally in meat and dairy products [55]. The feasibility of CLA supplementation in 335 
HIV-infected individuals has previously been investigated in a study carried out by our 336 
group. In this study, a mixed c9,t11 and t10,c12 supplement was used (Clarinol A80, Stepan 337 
Lipid Nutrition Ltd., Koog aan de Zaan, The Netherlands) at doses of 3 g per day for 12 338 
weeks. Due to the small sample size, this study has not been published, but details of the trial 339 
can be found on the ISRCTN clinical trial registry (DOI 10.1186/ISRCTN31131566).  340 
Limitations of the current study include the fact that RTV was investigated at 20 μM only; 341 
however, in vivo, circulating RTV levels are not sustained i.e. levels peak and trough. Future 342 
studies using different drug concentrations and over different time points would help to 343 
determine the potential effects of RTV at a range of therapeutic levels. Secondly, the use of 344 
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murine adipocytes limits the generalizability of the study and future studies with primary 345 
human adipocytes would enhance the clinical relevance of these findings. Additionally, no 346 
combinations of c9,t11 and t10,c12 were tried in the current study, as the focus of this initial 347 
work was to elucidate the effects of each isomer individually. Future studies should 348 
investigate the effect of the isomers in combination, given that both isomers increased TG 349 
accumulation, but only the t10,c12 isomer caused detrimental effects. The c9,t11 isomer is 350 
the most abundant dietary form, while commercial supplements typically consist of 351 
significant amounts of t10,c12 [56]. As each isomer was investigated separately, our 352 
experimental set-up used a common in vitro concentration. Although the dose used does not 353 
reflect plasma concentrations following dietary or supplementary CLA, it is within the range 354 
expected within adipocytes following dietary supplementation [2]. Future studies should also 355 
investigate RTV+c9,t11 in the presence of a PPAR-γ inhibitor such as GW9662, to determine 356 
whether the effects on TG accumulation occur via a PPAR-γ-dependent mechanism.  357 
 358 
Conclusion 359 
For the first time this study demonstrates an effect of CLA isomers in a model of HIV-360 
associated lipodystrophy. CLA isomers exerted differential effects on mRNA expression of a 361 
number of genes including PPAR-γ and adiponectin, but both isomers increased TG 362 
accumulation. Although, the effect of t10,c12 on TG accumulation may be viewed as 363 
potentially beneficial in the context of HIV lipoatrophy, the inhibitory effect of t10,c12 in the 364 
presence of RTV on key adipogenic genes argues against the use of t10,c12 in combination 365 
with antiretroviral drugs. The findings indicate the potential of the c9,t11 isomer to modulate 366 
PPAR-γ and potentially alleviate ARV-induced down-regulation of PPAR-γ, an important 367 
mechanism underlying HALS. Further research is required to explore this and to determine 368 
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whether c9,t11 should be pursued as a potential therapeutic agent in HIV-associated 369 
lipodystrophy. 370 
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Tables and figures 382 
 383 
FIGURE 1 
  
Figure 1 Gene Ontology processes affected by RTV + t10,c12-CLA. Significant 384 
representation in Gene Ontology probes indicated a change in gene expression between 385 
RTV+t10,c12 and control cells. These genes were categorised according to the gene ontology 386 
processes they formed part of. The Gene Ontology Terms significantly represented are 387 
shown. The length of each bar is proportional to the ratio of the number of genes altered 388 
compared with the total number of genes in the GO network. P < 0.001 for all Gene 389 
Ontologies shown.  390 
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FIGURE 2 
 
 
 
Figure 2 Gene Ontology processes affected by RTV + c9,t11-CLA. Significant 391 
representation in Gene Ontology probes indicated a change in gene expression between 392 
RTV+c9,t11 and control cells. These genes were categorised according to the gene ontology 393 
processes they formed part of. The Gene Ontology Terms significantly represented are 394 
shown. The length of each bar is proportional to the ratio of the number of genes altered 395 
compared with the total number of genes in the GO network. P < 0.001 for all Gene 396 
Ontologies shown.  397 
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Table 1 Gene probes altered within the main GO processes  
t10,c12 + RTV  
Fat cell differentiation: down-regulated genes 
Probe 
identification 
Gene name  Gene symbol Fold change 
1451371_at 
melanocortin 2 receptor accessory 
protein 
Mrap -8.25 
1449182_at resistin Retn -8.10 
1455918_at adrenergic receptor, beta 3 Adrb3 -6.36 
1435092_at ADP-ribosylation factor-like 4A Arl4a -4.84 
1439834_at Foxo1 corepressor FCoR -4.78 
1425215_at free fatty acid receptor 2 Ffar2 -4.58 
1415965_at stearoyl-Coenzyme A desaturase 1 Scd1 -4.34 
1460197_a_at STEAP family member 4 Steap4 -4.08 
1450699_at selenium binding protein 1  Selenbp1 -3.81 
1415958_at Glucose transporter type 4 Glut4 -3.67 
1434484_at WAP four-disulfide core domain 21 Wfdc21 -3.43 
1422651_at 
adiponectin, C1Q and collagen 
domain containing 
Adipoq -2.95 
1426858_at 
inhibin beta-B /// similar to Inhbb 
protein 
Inhbb /// 
LOC100046802 
-2.89 
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1428333_at Signal peptidase complex subunit 3 SPC22 -2.70 
1450718_at SH2B adaptor protein 2 Sh2b2 -2.56 
1418288_at lipin 1 Lpin1 -2.52 
1419030_at 
Endoplasmic Oxidoreductin-1-Like 
Protein 
Ero1l -2.49 
1422444_at integrin alpha 6 Itga6 -2.45 
1437345_a_at 
Bernardinelli-Seip congenital 
lipodystrophy 2 homolog (human) 
Bscl2 -2.29 
1423259_at inhibitor of DNA binding 4 Id4 -2.01 
Fat cell differentiation: up-regulated genes 
Probe 
identification 
Gene name  Gene symbol Fold change 
1450780_s_at high mobility group AT-hook 2 Hmga2 6.96 
1448698_at cyclin D1 Ccnd1 3.04 
1422053_at inhibin beta-A Inhba 2.09 
1421740_at 
GNAS (guanine nucleotide binding 
protein, alpha stimulating) complex 
locus 
Gnas 1.62 
c9,t11 + RTV 
Homophilic cell adhesion via plasma membrane adhesion molecules: up-regulated 
genes 
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Probe 
identification 
Gene name  Gene symbol Fold change 
1423628_s_at 
Protocadherin gamma subfamily 
A1-12, B1-7, C3-5 
Pcdhga 1-12, 
Pcdhgb 1-7, 
Pcdhgc 3-5 
1.50 
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FIGURE 3 
 
Figure 3 Effect of RTV and CLA isomers on PPAR-γ transcription. Adipocytes were treated 398 
with Cmax concentrations of RTV and DMSO or RTV and 100 μM of c9,t11 or t10,c12. 399 
Expression of PPAR-γ mRNA was measured on day 5 of differentiation relative to Hprt 400 
housekeeping gene by RT-PCR. Results represent mean ± SEM of quadruplicate cell culture 401 
experiments. Not significantly different from control cells.  402 
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FIGURE 4 404 
  
Figure 4 Effect of RTV and CLA isomers on adiponectin transcription. Adipocytes were 405 
treated with control or Cmax concentrations of RTV and DMSO or RTV and 100 μM CLA 406 
isomers, c9,t11 or t10,c12. Expression of adiponectin mRNA was measured on day 5 of 407 
differentiation relative to Hprt housekeeping gene by RT-PCR. Results represent mean ± 408 
SEM of quadruplicate cell culture experiments. *Significantly different (P = 0.038) from 409 
control cells. 410 
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FIGURE 5 
 
Figure 5 Effect of RTV and CLA isomers on nuclear PPAR-γ binding to PPRE. Nuclear 411 
proteins were extracted on day 5 of differentiation from adipocytes treated with control or 412 
Cmax concentrations of RTV and DMSO or RTV and 100 μM of c9,t11 or t10,c12 and nuclear 413 
PPAR-γ consensus site binding was measured. Results represent mean ± SEM of 414 
quadruplicate cell culture experiments. *Significantly different (P = 0.038) from control 415 
cells.  416 
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FIGURE 6 
 
Figure 6 Effect of RTV and CLA isomers on adiponectin protein secretion.  Adipocytes were 417 
treated with control or Cmax concentrations of RTV and DMSO or RTV and 100 μM CLA 418 
isomers, c9,t11 or t10,c12. Supernatants were collected from adipocytes on day 5 of 419 
differentiation and used to quantify adiponectin secretion. Results represent mean ± SEM of 420 
quadruplicate cell culture experiments. *Significantly different (P = 0.003) from control 421 
cells. 422 
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FIGURE 7A 
 
Figure 7 The effects of RTV and CLA isomers on TG accumulation in 3T3-L1 adipocytes. 423 
(A) Lipid content was measured spectrophotometrically at A 540 nm and is represented as 424 
mean ± S.E.M. of quadruplicate cell culture experiments. * Significantly different (P<0.001) 425 
from control cells. (B) Adipocytes treated with vehicle control (RTV+DMSO) or RTV with 426 
100 μM c9,t11 or t10,c12 were stained at day 5 with ORO to visualize lipid content 427 
[magnification is at 40x].  428 
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FIGURE 7B 
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